Should I buy or sell Cyclacel Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYCC shares. View CYCC analyst ratings or view top-rated stocks .

What is Cyclacel Pharmaceuticals' stock price target for 2024?

1 analysts have issued 12-month price objectives for Cyclacel Pharmaceuticals' stock. Their CYCC share price targets range from $8.00 to $8.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 2,582.8% from the stock's current price. View analysts price targets for CYCC or view top-rated stocks among Wall Street analysts .

How have CYCC shares performed in 2023?

Cyclacel Pharmaceuticals' stock was trading at $0.6670 at the beginning of the year. Since then, CYCC stock has decreased by 55.3% and is now trading at $0.2982. View the best growth stocks for 2023 here .

When is Cyclacel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our CYCC earnings forecast .

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) released its earnings results on Monday, March, 6th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.12.

When did Cyclacel Pharmaceuticals' stock split?

Cyclacel Pharmaceuticals shares reverse split on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 14th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?

1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com . Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , Inovio Pharmaceuticals (INO) , Vaxart (VXRT) , NVIDIA (NVDA) , Novavax (NVAX) , Gilead Sciences (GILD) , Heat Biologics (HTBX) , McEwen Mining (MUX) and Tesla (TSLA) .

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Cyclacel Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CYCC)

$0.30

+0.01 (+3.47%)

(As of 11/28/2023 ET)

Compare

Today's Range: $0.28
▼
$0.32
50-Day Range: $0.27
▼
$0.75
52-Week Range: $0.27
▼
$1.17

Volume: 167,024 shs
Average Volume: 91,310 shs
Market Capitalization: $3.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Cyclacel Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 2,582.8% Upside
$8.00 Price Target
Short Interest: Healthy
4.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.61
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.76) to ($3.68) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Cyclacel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, Cyclacel Pharmaceuticals has a forecasted upside of 2,582.8% from its current price of $0.30.
Amount of Analyst Coverage
Cyclacel Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.87% of the float of Cyclacel Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cyclacel Pharmaceuticals has recently increased by 1.15%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Cyclacel Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Cyclacel Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CYCC.

2.6

News and Social Media Coverage

News Sentiment
Cyclacel Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Cyclacel Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
5 people have searched for CYCC on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.47% of the stock of Cyclacel Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 16.33% of the stock of Cyclacel Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cyclacel Pharmaceuticals are expected to decrease in the coming year, from ($1.76) to ($3.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cyclacel Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cyclacel Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cyclacel Pharmaceuticals has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

CYCC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CYCC Stock News Headlines

November 28, 2023 | benzinga.com

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

November 28, 2023 | finance.yahoo.com

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 27, 2023 | msn.com

Cyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94

November 24, 2023 | morningstar.com

Cyclacel Pharmaceuticals Inc CYCC

November 24, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)

October 19, 2023 | msn.com

Cyclacel Pharmaceuticals, Inc. PFD CONV EX 6% goes ex dividend tomorrow

August 9, 2023 | msn.com

Cyclacel Pharmaceuticals GAAP EPS of -$0.44 beats by $0.06, revenue of $0.37M

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

August 9, 2023 | finance.yahoo.com

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

August 3, 2023 | finance.yahoo.com

Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

July 13, 2023 | finance.yahoo.com

Cyclacel Pharmaceuticals, Inc. (CYCC) Upgraded to Strong Buy: Here's Why

June 15, 2023 | forbes.com

Jointown Pharmaceutical Group

May 26, 2023 | msn.com

Oppenheimer Maintains Cyclacel Pharmaceuticals (CYCC) Outperform Recommendation

May 3, 2023 | finance.yahoo.com

Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit

March 8, 2023 | finance.yahoo.com

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2022 Earnings Call Transcript

March 7, 2023 | msn.com

Oppenheimer Maintains Outperform Rating for Cyclacel Pharmaceuticals: Here's What You Need To Know

March 3, 2023 | msn.com

A Preview Of Cyclacel Pharmaceuticals's Earnings

January 30, 2023 | finance.yahoo.com

Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference

December 15, 2022 | finance.yahoo.com

Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023

November 9, 2022 | seekingalpha.com

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Call Transcript

November 8, 2022 | msn.com

Earnings Outlook For Cyclacel Pharmaceuticals

November 7, 2022 | finance.yahoo.com

Here's What to Expect Ahead of Wix's (WIX) Q3 Earnings Release

October 26, 2022 | finance.yahoo.com

Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022

October 14, 2022 | fool.com

Cyclacel Pharmaceuticals (NASDAQ: CYCC)

October 13, 2022 | finance.yahoo.com

Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium

August 11, 2022 | seekingalpha.com

Cyclacel stock rises 16% as net loss narrows, income grows

See More Headlines

Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2023
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CYCC
CUSIP: N/A
CIK: 1130166
Web: www.cyclacel.com
Phone: (908) 517-7330
Fax: 866-271-3466
Employees: 2,018
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $8.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +2,582.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,200,000.00
Net Margins: N/A
Pretax Margin: -7,578.55%
Return on Equity: -241.30%
Return on Assets: -112.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.27
Quick Ratio: 2.27

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.24 per share
Price / Book: 0.24

Miscellaneous

Outstanding Shares: 12,640,000
Free Float: 11,572,000
Market Cap: $3.77 million
Optionable: Not Optionable
Beta: 1.06

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Spiro George Rombotis (Age 64)
President, CEO & Executive Director
Comp: $763.55k
Mr. Paul McBarron (Age 62)
Executive VP of Finance, CFO, COO, Secretary & Executive Director
Comp: $394.68k
Dr. Mark H. Kirschbaum M.D. (Age 62)
Senior VP & Chief Medical Officer
Comp: $523.84k
Ms. Gill Christie (Age 66)
Director of Human Resources

Key Competitors

View All Competitors

CYCC Stock Analysis - Frequently Asked Questions

Should I buy or sell Cyclacel Pharmaceuticals stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYCC shares.
View CYCC analyst ratings or view top-rated stocks.
What is Cyclacel Pharmaceuticals' stock price target for 2024?: 1 analysts have issued 12-month price objectives for Cyclacel Pharmaceuticals' stock. Their CYCC share price targets range from $8.00 to $8.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 2,582.8% from the stock's current price.
View analysts price targets for CYCC or view top-rated stocks among Wall Street analysts.
How have CYCC shares performed in 2023?: Cyclacel Pharmaceuticals' stock was trading at $0.6670 at the beginning of the year. Since then, CYCC stock has decreased by 55.3% and is now trading at $0.2982.
View the best growth stocks for 2023 here.
When is Cyclacel Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our CYCC earnings forecast.
How were Cyclacel Pharmaceuticals' earnings last quarter?: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) released its earnings results on Monday, March, 6th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.12.

When did Cyclacel Pharmaceuticals' stock split?: Cyclacel Pharmaceuticals shares reverse split on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 14th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?: 1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Cyclacel Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).
How do I buy shares of Cyclacel Pharmaceuticals?: Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CYCC) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial